Gout Management
Introduction to Urate-Lowering Therapy
- High-quality evidence shows that prophylactic therapy with low-dose colchicine or NSAIDs reduces the risk for acute gout attacks in patients initiating urate-lowering therapy, according to the American College of Physicians 1
- Moderate-quality evidence suggests that continuing prophylactic treatment for more than 8 weeks is more effective than shorter durations, as recommended by the American College of Physicians 1
Safety and Efficacy of Febuxostat
- The most common adverse events associated with febuxostat include liver function abnormalities, abdominal pain, diarrhea, musculoskeletal pain, and rash 1
- The safety profile of febuxostat for long-term use is less established than that of allopurinol, according to the American College of Physicians 1
- There is more uncertainty about the harms of febuxostat compared to allopurinol due to limited long-term safety data 1
Prevention of Gout Flares
- Use of low-dose colchicine (0.6 mg twice daily) or NSAIDs for at least 8 weeks when starting febuxostat is recommended to prevent gout flares, based on guidelines from the American College of Physicians 1
- Longer prophylaxis duration (>8 weeks) is more effective at reducing gout flares 1
Urate-Lowering Therapy with Febuxostat
- Febuxostat is an effective second-line urate-lowering therapy for chronic gout management, particularly beneficial in patients who cannot tolerate allopurinol or have renal impairment, though it should be used with caution due to potential cardiovascular risks 1, 2
- High-quality evidence shows febuxostat effectively reduces serum urate levels 1, 2
- Febuxostat 80 mg/day is more effective than allopurinol 300 mg/day at decreasing serum urate levels, while no significant difference in efficacy is seen between febuxostat 40 mg/day and allopurinol 300 mg/day 2, 1
- Gout flare incidence is higher with high doses of febuxostat (120 or 240 mg/day) compared to allopurinol (100-300 mg/day), but no difference is seen between lower doses of febuxostat (40 or 80 mg/day) and allopurinol 1
Monitoring and Treatment Recommendations
- Patients should be monitored for signs and symptoms of myocardial infarction and stroke, and check serum urate levels to assess efficacy, monitor liver function tests, and assess for cardiovascular symptoms 1
- Consider allopurinol as initial therapy for most patients with gout requiring urate-lowering therapy, and consider febuxostat when patient has intolerance or hypersensitivity to allopurinol, moderate renal impairment, or fails to achieve target serum urate levels with allopurinol, as recommended by the American College of Physicians 1